Any new changes to the website will be highlighted below:

  • PROTHIONAMIDE Paediatric and adult dosing has been adjusted and made clearer.  11.6.14
  • DELAMANID Monograph NOW AVAILABLE 14.6.14
  • Patient information leaflet on MDR-TB drug treatment produced in collaboration with TB Alert, the British Thoracic Society and NHS now available to download from our home page, TB Alert page link to follow. 24.10.14
  • AMIKACIN If Amikacin needs to be given IM rather than IV we recommend this is once daily (to ensure appropriate peak levels) but due to large volumes this once daily dose needs to be administered as two injections. 1.12.14
  • AMIKACIN, CAPREOMYCIN, STREPTOMYCIN & ETHAMBUTOL advise regarding dosing in obesity has changed. 16.1.15
  • RIFAPENTINE Monograph NOW AVAILABLE 16.1.15
  • LEVOFLOXACIN Updated dosing info based on WHO 2014 DRTB guidelines (advises larger doses for children <5yrs as they metabolise levofloxacin faster than >5yr olds) 6.3.15
  • STREPTOMYCIN Updated dosing based on WHO 2014 DRTB guidelines. 6.3.15
  • PAS Updated dosing information for children. 6.3.15
  • MEROPENEM Updated dosing information for children. 6.3.15
  • CLOFAZIMINE Updated dosing information for children. 6.3.15
  • LINEZOLID Updated adverse effect monitoring guidance following several recent publications (see references section). 16.7.15
  • BASELINE & GENERIC TESTS Updated guidance on ECG and visual monitoring 7.9.15
  • ISONIAZID Altered units for measuring levels 8.12.15
  • Patient information leaflet on MDR-TB drug treatment produced in collaboration with TB Alert - updated version available 8.12.15
  • Link to WHO MDR TB guideline updated to 2016 guideline 11.8.16
  • Obesity dosing for ETHAMBUTOL 21.2.2017
  • Drug level monitoring for MOXIFLOXACIN 21.2.2017
  • Links to MDR-TB short course WHO & BTS advice added to home page 21.2.2017
  • Advice on ADR monitoring for ETHAMBUTOL updated 22.6.17
  • Child-friendly fixed dose combinations recommended by UNICEF and WHO added to RIFAMPICIN, ISONIAZID and PYRAZINAMIDE monographs 22.6.17
  • Dose changes advocated by WHO for MDR-TB shorter course regimen added to MOXIFLOXACIN monograph 22.6.17
  • Generic version of the home isolation guide uploaded to For Patients page 22.1.2018
  • Update to ongoing monitoring recommendations. 7.6.18
  • Introduction of guidance on lactate measurement in those vomiting, particularly those on LINEZOLID 7.6.18
  • Tinnitus has been detailed as a specific symptom of ototoxicity in the ongoing monitoring recommendations and the amikacin, Capreomycin, streptomycin monographs. 7.6.18
  • Delaminid included in list of drugs that prolong QTc in ongoing monitoring recommendations - previously this had been missed. 7.6.18
  • Link to QTc drugs website, HIV drug interactions and hepatitis drug interactions websites from ongoing monitoring recommendations 7.6.18
  • Cycloserine - recommendation for post level dose increased to 3 to 4 hours.30.7.18
  • New advice from WHO regarding classification of MDR-TB drugs published on the home page and on particular drug pages e.g. capreomycin which is no longer recommended 24.8.18
  • Terizidone monograph added due to difficulties in supply of cycloserine. Terizidone is a structural analog that is a combination of two cycloserine molecules. 26.4.20